[HTML][HTML] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte–associated antigen 4

KE Beck, JA Blansfield, KQ Tran… - Journal of clinical …, 2006 - ncbi.nlm.nih.gov
KE Beck, JA Blansfield, KQ Tran, AL Feldman, MS Hughes, RE Royal, US Kammula…
Journal of clinical oncology: official journal of the American Society …, 2006ncbi.nlm.nih.gov
Purpose Cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) is an inhibitory receptor on
T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms
in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4
antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-
mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and
significance of the immune-mediated enterocolitis seen with ipilimumab is presented.
Abstract
Purpose
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented.
ncbi.nlm.nih.gov